CAP-1, developed by Cellaster is a first-in-class drug targeting the root cause of metastasis-EPB41L5-driven EMT. Thru its dual mechanism, CAP-1 not only suppresses metastasis, but also restores immune responsiveness in resistant tumors.
Cellaster Inc.
CAP-1, developed by Cellaster is a first-in-class drug targeting the root cause of metastasis-EPB41L5-driven EMT. Thru its dual mechanism, CAP-1 not only suppresses metastasis, but also restores immune responsiveness in resistant tumors.